AMAnna E. Merrill

Anna E. Merrill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna E. Merrill has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Interpretive Challenges in Electrophoretic and Mass Spectrometric Methods for Monoclonal Gammopathy Detection in Patients with Cold Agglutinin Disease

    by Abdalla M Abdalla, Mohammed N Ibrahim, Nicholas G Paciaroni, Jodi V Mones, Anna E Merrill, Shelby M Hutcherson

  • ADLM Guidance Document on Coagulation Testing in Patients Using Direct Oral Anticoagulants

    by Lindsay A L Bazydlo, Maximo J Marin, Anna E Merrill, Louise M Man, Olajumoke O Oladipo, Neil S Harris

    Background: Coagulation testing has an important role in the diagnosis, monitoring, and therapeutic decision-making for patients with abnormal hemostasis. As the field of anticoagulation options has expanded, the introduction of direct oral anticoagulant (DOAC) drugs has provided an option for patients utilizing drugs that do not require routine monitoring. Patients on these drugs may still need coagulation testing for prognostic purposes, and there are a number of nuances to consider when performing coagulation testing in patients who are prescribed DOACs. Content: This document provides guidance on the tests that may or may not be impacted by the presence of DOACs in the blood. A discussion is provided about specific coagulation tests used and the impact of testing samples with a DOAC present. Options are presented to help mitigate the impact of DOACs on the testing. In addition, this document discusses how to test for and interpret DOAC concentrations in specific patient populations.


  • Improving Pleural Fluid pH Accuracy: A Quality Improvement Initiative

    by Sydney M Bowmaster, Anna E Merrill, Nicole L Manning, Jeffrey S Wilson, Thomas J Gross

    Background: Fluid pH remains a standard test when evaluating pleural effusions. Studies recommend using a blood gas analyzer to measure fluid pH immediately after sample collection. Centralization of laboratory services at our institution led to migration of blood gas analysis to a single core laboratory with uncertain impacts on pH results. Methods: Pleural fluid samples were obtained from 30 patients during routine clinical care, excluding those with frank purulence or blood. Fluid pH and pCO2 were measured on a blood gas analyzer. We compared samples collected in plastic screw-top vials from commercially available thoracentesis kits vs paired samples collected in blood gas syringes. We also examined how differences in processing time, fluid pCO2, and heparin anticoagulant correlated with measured pH. Results: Of the 30 paired samples obtained, 25 (83.3%) were exudates and 5 (16.7%) were transudates. All samples collected in blood gas syringes had lower mean pH and higher mean pCO2 than samples collected in plastic screw-top vials (mean pH difference ± SD, 0.16 ± 0.06; P < 0.001) (mean pCO2 difference ± SD, 14.09 ± 6.92; P < 0.001). Differences in fluid pH were independent of total nucleated cell count (range 65–28 380 cells/mm3). Neither the presence of heparin in the syringe nor time delays up to 2 h between collection and analysis meaningfully impacted the pH result (P = 0.51 and P = 0.75, respectively). Conclusion: To accurately measure pleural fluid pH, specimens should be collected anaerobically in blood gas syringes rather than the screw-top vials provided in thoracentesis kits.

  • Open Access

    Complex Hyponatremia in a Cancer Patient with Hypercholesterolemia

    by Anna E Merrill, Jonathan R Day, Tanner J Simonson, Jeffrey W Meeusen, Leslie J Donato

  • The 2024 PhD Board-Certified Clinical Chemist Compensation Survey

    by Jaime H Noguez, Anna E Merrill, Adam J McShane, Yachana Kataria

    Background: Board-certified clinical chemists with doctor of philosophy (PhD) degrees are essential to laboratory medicine and healthcare, yet comprehensive data on their total compensation is limited. The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) Society for Young Clinical Laboratorians Core Committee conducted its fifth compensation survey in April 2024, providing updated data on salary, benefits, and job satisfaction among board-certified clinical chemists. Methods: The 2024 compensation survey was distributed to all doctoral-level ADLM members based in the United States and Canada (n = 1576). Confidential, self-reported data were collected from respondents on various demographic and professional characteristics, including academic degree, board certification, years of experience, employment sector, total compensation (defined as base salary plus bonus), geographic location, race/ethnicity, and sex. The study included a total of 291 respondents for analysis. Results: Ninety-two percent (n = 267) of the respondents resided in the United States and 90% held a PhD degree. More than half of the respondents were employed in academic, hospital, or healthcare system settings. Among those with board certification, 86% were certified by the American Board of Clinical Chemistry (ABCC). The median total compensation for ABCC board-certified PhD clinical chemists working in the United States (n = 158) was $220 000 to $229 000. Conclusions: The 2024 survey highlights a continued upward trend in compensation for board-certified PhD clinical chemists, reflecting their expertise and contributions to healthcare. This report serves as a critical resource for professionals to advocate for equitable and competitive compensation as well as benefits that support career advancement and development.

  • Open Access

    Increasing the Diagnostic Utility of Heparin-Induced Thrombocytopenia (HIT) Testing: An Academic Medical Center’s Utilization Analysis and Intervention

    by Meredith G Parsons, Ryan A Hobbs, Julie Schmidt, Anna E Merrill

    Background: Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening adverse drug reaction with numerous diagnostic challenges. Diagnosis of HIT begins with 4T score clinical assessment, followed by laboratory testing for those not deemed low risk. Laboratory testing for HIT includes screening [enzyme-linked immunosorbent assay (ELISA)] and confirmatory [serotonin release assay (SRA)] assays, wherein SRA testing can be pursued following a positive ELISA result. These tests aid diagnosis of HIT, but also introduce interpretive challenges, additional costs, and delays in clinical intervention. Methods: A retrospective review of 1011 HIT ELISA and 169 SRA tests performed over 5 years was conducted. ELISA percent inhibition and ELISA low-heparin optical density (OD) were evaluated for positive predictive value (PPV). Based on these findings, HIT ELISA reporting and management algorithm changes were implemented and metrics compared for 5 months pre- and post-intervention to assess intervention success. Results: Equivocal and positive HIT ELISA interpretation showed poor PPV based on percent inhibition (0.20 and 0.32, respectively). However, rising low-heparin OD correlated with increasing PPV (PPV of 0.00 for OD values 0.40–1.00, 0.29 for values 1.00–1.99, and 0.91 for values >2.00). Data-driven intervention decreased ELISA positivity rates (13% to 5%), decreased rates of SRA confirmatory testing overall (13% to 9%), decreased SRA testing rates for patients with non-negative ELISAs (78% to 43%), and increased heparin resumption (20% to 57%). Hematology consults remained relatively stable (78% and 86%). Conclusions: Low-heparin OD-based HIT ELISA interpretation yielded enhanced PPV compared with percent inhibition-based interpretation. Implementation of data-driven changes improved testing stewardship and clinical management for patients with non-negative ELISAs.


  • Open Access

    Fluctuating von Willebrand Factor Activity in a Young Adult

    by Meredith G Parsons, Anna E Merrill

    A 30-year-old female presented with abdominal pain, oliguria, severe thrombocytopenia (4 × 109/L), elevated creatinine (6.1 mg/dL; 539 µmol/L), elevated lactate dehydrogenase (1,673 U/L), 3+ schistocytes, and nearly absent ADAMTS13 activity (2%), consistent with immune-mediated thrombotic thrombocytopenic purpura (TTP). Daily plasma exchange (PLEX) and caplacizumab were initiated day 2, with laboratory monitoring shown in Table 1.

  • Beyond the Screen: Navigating Remote Work within Medicine

    by Anna E Merrill, Sarah A Hackenmueller, Colin Derdeyn, Jonathan Genzen, Damien Gruson, Melissa Ludgate, Surabhi Mulchandani, M Laura Parnas, Erik Ranheim

    The onset of the COVID-19 global pandemic in 2020 brought abrupt changes to how people lived their lives and interacted with society. Many activities and jobs that did not require face-to-face interactions were shifted to remote or distanced formats. While certain aspects of healthcare require in-person interactions, the pandemic triggered a rapid expansion of telemedicine for areas where it was feasible to do so. Additionally, many non-patient facing roles that did not necessitate an onsite presence were converted to remote work. The necessity of rapidly converting compatible healthcare activities to remote work initially outweighed maintaining the status quo. As in-person activities have increased with the receding pandemic, many industries that adopted remote work solutions, including healthcare, now face the challenge of navigating reintegration of remote or hybrid options with onsite work. Many employees prefer remote or hybrid work solutions, but there are potential limitations associated with widespread implementation of these models that are not fully understood due to their relative infancy. Even so, remote and hybrid activities appear to be permanent changes to how we work.